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Background: The benzothiazole structure is important in medicinal chemistry, and
5‐fluoro‐2‐(3,4‐dimethoxyphenyl) benzothiazole (GW 610) is of particular interest as
it shows outstanding anticancer activity in sensitive breast and colorectal carcinoma
cell lines via generation of lethal DNA adducts in sensitive cancer cells. Despite
promising activity, poor water solubility limits its applications. The apoferritin (AFt)
protein cage has been proposed as a robust and biocompatible drug delivery vehicle.
Aims: Here, we aim to enhance solubility of GW 610 by developing amino acid
prodrug conjugates and utilizing the AFt capsule as drug delivery vessel.
Methods and results: The potent experimental antitumour agent, GW 610, has
been successfully encapsulated within AFt with more than 190 molecules per AFt
cage. The AFt‐GW 610 complex exhibits dose‐dependent growth inhibition and is
more potent than GW 610 alone in 5/7 cancer cell lines. To enhance both aqueous
solubility and encapsulation efficiency, a series of amino acid esters of GW 608
prodrug were synthesized via N,N′‐dicyclohexylcarbodiimide ester coupling to pro-
duce molecules with different polarity. A dramatic increase in encapsulation efficiency
was achieved, with more than 380 molecules of GW 608‐Lys molecules per AFt cage.
Release studies show sustained release of the cargo over 12 hours at physiologically
relevant pH. The AFt‐encapsulated amino acid modified GW 608 complexes are
sequestered more rapidly and exhibit more potent anticancer activity than
unencapsulated agent.
Conclusion: These results indicate that AFt‐encapsulation of GW 610 prodrug pro-
vides a biocompatible delivery option for this potent, selective experimental
antitumour agent and for amino acid‐modified GW 608. Of particular interest is the
encapsulation efficiency and in vitro antitumour activity of AFt‐GW 608‐Lys, which
warrants further preclinical evaluation.
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Advancement of novel pharmaceutical agents to the market is often
thwarted by lack of selectivity and solubility in physiological solvents.
Various nanoscale delivery vehicles have been considered to address
these issues, such as liposomes, micelles, and protein capsules. Of par-
ticular interest is protein capsule apoferritin (AFt), which has been suc-
cessfully used for development of biohybrid and self‐assembled
materials,1,2 for the encapsulation of proteins3 and small drug mole-
cules.4-8 AFt consists of 24 polypeptide subunits assembled into a
spherical protein cage with an internal cavity of 8 nm in diameter9;
0.3‐ to 0.4‐nm channels in the shell10 and pH‐dependent dissembly9
allow controlled release of cargo. The uniform size, biocompatibility,
biodegradability, and non‐toxicity has led to AFt being identified as an
ideal drug delivery vehicle.11 AFt is internalized into cells by transferrin
receptor (TfR)‐mediated endocytosis; TfRs are upregulated and highly
expressed on cell membranes in many cancers (including colon and
breast cancinomas).12 AFt as a drug delivery vehicle can lead to
enhanced delivery to cancer tissue, via exploitation of the enhanced
permeability and retention (EPR) associated with the tumour micro‐
environment,13 leading to increased intracellular drug concentrations
within a tumour, improving the therapeutic efficacy and decreasing side
effects.14
The benzothiazole structure is important in medicinal chemistry, as
derivatives of this scaffold possess anticancer,15 antibacterial,16 antiviral,17
antimalarial,18 and antifungal19 activity. From this scaffold, a chemistry‐
driven drug discovery project resulted in the development of a wide range
of2‐phenylbenzothiazoleswithoxygenated substituents in thephenylmoi-
ety. In a library of more than 35 close structural analogues, one compound
5‐fluoro‐2‐(3,4‐dimethoxyphenyl) benzothiazole (GW 610), showed out-
standing potent and selective anticancer activity against, eg, colorectal
and breast carcinoma models.15 GW 610 is a potent aryl hydrocarbon
receptor (AhR) ligand, bioactivated via cytochrome P450 (CYP) 1A1 and
2W1 catalysis to electrophilic species that generate lethal DNA adducts
in sensitive cancer cells.20-22
However, GW 610 is highly lipophilic and poorly water soluble;
hence, drug delivery tools are needed to help solubilize and target
GW 610. During biotransformation, GW 610 initially undergoes
regiospecific demethylation to give 5‐fluoro‐2‐(4‐hydroxy‐3‐
methoxyphenyl) benzothiazole (GW 608).21 The exposed 4′‐hydroxy
group in GW 608 allows conjugation of substituents via an ester link-
age to the benzothiazoles and could lead to enhanced aqueous solubil-
ity and stability, whilst retaining antitumour activity.
We report AFt encapsulation of GW 610, GW 608, and amino
acid conjugates of GW 608 to address water solubility and selectivity
issues associated with benzothiozoles for anticancer treatment. Amino
acid conjugation enhances drug solubility and modifies the charge and
polarity, thus allowing optimization of the properties of cargo mole-
cules to achieve increased encapsulation efficiency and controlled
sustained release. In this work, we consider nonpolar glycine (Gly),
polar serine (Ser), positively charged lysine (Lys), and negatively
charged aspartic acid (Asp) conjugated to GW 608. The in vitro
antitumour activity of the AFt formulations was investigated against
MDA‐MB‐468, MCF‐7 breast, IGROV‐1 ovarian, TK10 renal, KM‐12,
HCC‐2998, and HCT 116 colorectal carcinoma (CRC) cell lines. Ourstudy of novel benzothiazole formulations reveals exciting prospects
for their development as anticancer agents.2 | RESULTS AND DISCUSSION
2.1 | Synthesis and AFt encapsulation of amino acid
conjugates of GW 608
GW 610 and its derivatives were synthesized following a modified
procedure developed by Mortimer et al23 (see Supporting Information
S1). The common intermediate, 6,6′disulphide bis(3‐fluroaniline) was
obtained via a three‐step reaction. Briefly, 3‐fluoroaniline was refluxed
in acetone with benzoyl chloride and ammonium thiocyanate to yield
1‐(3‐fluorophenyl) thiourea, followed by bromination ring closure to
give 2‐amino‐5‐fluorobenzothiazole. This was then converted by
hydrolysis with aqueous potassium hydroxide to give the common
intermediate. The disulphide was refluxed with the corresponding
benzaldehyde and triphenylphosphine with catalytic amounts of p‐
toluenesulphonic acid. GW 608 amino acid esters (Figure 1A) were
produced by coupling GW 608 with the corresponding Boc or
Boc/tBu protected amino acid, via a N,N′‐dicyclohexylcarbodiimide
(DCC) ester coupling under dichloromethane reflux. The protecting
groups were removed by 4M HCl in dioxane, to give the GW 608
amino acid esters.
All agents were encapsulated into AFt cavities using the
nanoreactor method (Figure 1B and Supporting Information S2). The
test agent was added to AFt solution in aliquots with time interval
of 30 minutes over a period of 5 hours to avoid protein precipitation
and to increase the encapsulation efficiency. Because of the hydro-
phobic nature of benzothiazoles, the preferred uptake route is likely
to be via passive diffusion through the hydrophobic channels in the
AFt shell.10 The encapsulation was assessed by UV‐vis absorption
and confirmed with 19F‐NMR (see Supporting Information S2). We
achieved encapsulation of approximately 190 molecules of GW 610
and approximately 110 molecules of GW 608 per AFt cage. We
ascribe the observed difference to the increased polarity of GW 608,
which hinders encapsulation into AFt with a negatively charged cav-
ity.24 We note, that encapsulation following one‐step addition of the
full quantity of test agent reported in the literature25,26 resulted in
reduced drug loading values, comparable to those published.
For GW 608 derivatives, we also observe some differences in
encapsulation efficiency, with approximately 310 GW 608‐Gly and
approximately 206 GW 608‐Ser molecules per AFt cage. With the
encapsulation procedure carried out at approximately 7.4 pH and
the pKa of the amino groups approximately 9, the overall charge on
both agents is likely to be +1. It suggests that increased polarity neg-
atively impacts encapsulation, when comparing related structures
(GW 610 vs GW 608 and GW 608‐Gly vs GW 608‐Ser). However,
charge also affects the encapsulation, with 180 and 380 molecules
per AFt capsule of GW 608‐Asp and GW 608‐Lys, respectively. The
approximate pKa values of the Asp and Lys side chains are 4 and
10 respectively, so the overall charges on GW 608‐Asp and GW
608‐Lys are likely to be 0 and +2. Hence, GW 608‐Lys interacts
with the negatively charged AFt interface, leading to enhanced
FIGURE 1 A, Chemical structure of synthesized benzothiazole derivatives. B, Schematic representation of diffusion driven encapsulation of GW
610 into AFt. C, Release profiles of GW 610 and GW 608‐Lys from AFt cavity at 37°C and pH 6.5 (red circles) and 7.4 (black circles)
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of charge and polarity of the agent enabled us to achieve approxi-
mately two orders of magnitude greater encapsulation efficiency
(386 molecules) per AFt cage compared with that reported for gefi-
tinib,26 doxorubicin,8,25 or cisplatin.27 Improved doxorubicin encapsu-
lation via the reassembly route was recently reported for fusion
protein HFt‐PAS, achieving 90 molecules per cage8; hence, our encap-
sulation method offers an advantageous approach for enhanced drug
loading.
The poor aqueous solubility of GW 610 was evident from low
drug loading of approximately 11%. Improved solubility of the amino
acid conjugates increased drug loading more than twofold, with
highest value of 25% for the Lys‐conjugate. These results confirm
that conjugation with amino acids increases encapsulation efficiency
due to favourable polarity and enhanced aqueous solubility.
All encapsulated test agents were stable over a period of at least
3 months with respect to drug loading when stored at T = 4°C, as
quantified by UV‐vis spectroscopy. For samples stored at room tem-
perature, drug release of up to approximately 50% was observed after7 days storage. At physiologically relevant temperature (T approxi-
mately 37°C), all test agents were released from the AFt cage with
100% release observed within 12 hours (Figure 1C). Considering the
structural sensitivity of AFt to pH,13 faster release may be anticipated
at acidic pH 6.5 associated with tumour micro‐environments. How-
ever, negligible effect was observed for GW 610 release; indeed, more
rapid release of GW 608‐Lys at pH 7.4 compared with pH 6.5 was
encountered. We postulate that as pH decreases, the proportion of
unionized species on Lys reduces, resulting in greater interaction with
the negatively charged AFt interior, impeding GW 608‐Lys release.
Hence, steady release of benzothiazoles occurs over 12 hours at phys-
iologically relevant pH and is controlled by electrostatic interactions
between the agent and the AFt.2.2 | In vitro assessment of therapeutic activity
MTT in vitro growth inhibitory assays were performed to probe the
effects of amino acid conjugation and AFt‐encapsulation on anticancer
TABLE 1 Summary of selected GI50 values taken from MTT (72‐h expos
Test Agent
Mean
MCF‐7 MDA‐468 TK10 I
GW 610 0.006 ± 0.004 0.034 ± 0.026 0.57 ± 0.16 3
AFt‐GW 610 0.39 ± 0.33 0.12 ± 0.07 0.14 ± 0.10 0
GW 608‐Lys 29.2 ± 20.6 0.43 ± 0.29 34.1 ± 14.5 4
AFt‐GW 608‐Lys 1.72 ± 0.32 0.042 ± 0.037 0.60 ± 0.35 0
aGI50 is mean ± standard deviation (SD) from the three trials, where n = 4 per
FIGURE 2 A, Representative dose response curves for KM‐12 cells
after 72‐h exposure to GW 610 vs AFt‐GW 610 and GW 608‐Lys
vs AFt‐GW 608‐Lys. B, Survival fractions of colonies estimated as a
percent of untreated control after 24‐h exposure to GI50
concentration of the agent followed by 7‐day growth. C, Summary
of GI50 values for representative cell lines for GW 608‐Lys vs AFt‐
GW 608‐Lys. The results are mean ± standard deviation (SD) for
n = 4 in one representative trial; number of independent trials is 3;
*P < 0.01
4 of 7 BREEN ET AL.activity of GW 610. The cell line panel included breast, renal, ovarian,
and CRC cell lines. Following 72‐hour exposure, AFt‐GW 610 elicits
dose‐dependent growth inhibition against the same cells lines as GW
610 alone; thus, selectivity is retained (Figure 2, Table 1, and Supporting
Information S3). AFt‐encapsulated GW 610 is more potent than naked
agent in 5/7 cell lines; remarkably, approximately 50‐fold enhanced
potency against KM‐12 was observed. In MCF‐7 and MDA‐468, naked
GW 610 was more potent than AFt‐encapsulated GW 610, possibly a
consequence of abundant cytosolic AhR, which following intracellular
diffusion of lipophilic GW 610, results in its rapid sequestration by
MCF‐7 and MDA‐468 cells28 and subsequent rapid AhR signal trans-
duction cascade activation. Correlating with greater potency of naked
GW610 cf AFt‐GW610, the proportion of cells with internalized naked
GW610was greater than that of AFt‐GW610 inMCF‐7 andMDA‐468
cells (Figure 3A and Supporting Information S3).
More polar GW 608 was significantly less potent than GW 610 in
all cell lines tested (Table S2) and completely inactive in some cell lines.
Reduced lipophilicity of GW608 is likely to impede diffusion across cell
membranes and, combined with potentially lower affinity for AhR,
impact negatively on intracellular retention and AhR signal transduction
activation.
Conjugation to amino acids increased the potency of GW 608 in all
GW 610‐sensitive carcinoma cell lines studied (Table 1 and Supporting
Information S3).
Consistent with the selective nature of benzothiazole anticancer
activity, negligible activity was observed in insensitive HCT‐116 CRC
cells and nontransformed MRC‐5 fibroblasts (GI50 > 100μM) (Table 1
and Supporting Information S3), which express neither inducible nor
constitutive CYP 1A1 or CYP 2W1. Following encapsulation, the
potency of amino acid conjugates was further enhanced comparedwith
the naked agents; furthermore, the selectivity of GW 610was retained.
The AFt‐GW 608‐Gly and AFt‐GW 608‐Ser are both more active than
AFt‐GW 610 in MDA‐468 and KM‐12, respectively. AFt‐GW 608‐Lys
demonstrated greater activity than AFt‐GW 610 in 4/7 cell lines:
MDA‐468, IGROV‐1, KM‐12, and HCC‐2998. Remarkably, following
AFt‐encapsulation of GW 608‐Lys, potency enhanced approximately
1000‐fold in KM‐12 cells, and a mean GI50 value of 0.13μM was
achieved (Figure 2).
Potency of AFt‐GW 608‐Lys cf GW 608‐Lys in sensitive cell lines
(Figure 2C) generally correlates with cellular uptake. Cellular uptake of
GW 610/GW 608‐Lys was assessed by flow cytometry. We exploited
the fluorescent chromophore of the benzothiazole molecule, quantify-
ing the number of cells within the population with detectable fluores-
cence.29 Cells, seeded at the same density, were treated with
benzothiazole test agent at a final concentration of 1μM. Analysisure) assaya
GI50 values ± SD, μM
GROV‐1 KM‐12 HCC‐2998 HCT‐116 MRC‐5
.37 ± 1.68 22.0 ± 6.03 0.32 ± 0.26 27.1 ± 14.3 >100
.48 ± 0.44 0.45 ± 0.34 0.11 ± 0.03 2.29 ± 0.67 >100
.36 ± 0.41 >100 9.75 ± 11.5 >100 >100
.40 ± 0.10 0.13 ± 0.12 0.10 ± 0.04 >4.10 >100
trial.
FIGURE 3 Proportion of cells with intracellular agent in MDA‐468,
IGROV‐1, and TK10 carcinoma cell lines and MRC‐5 fibroblasts
determined as number of cells with detectable fluorescence of the
agent. Cells treated with 1μM concentration of test agent for 3 and
9 h. Results are shown for test agents A, GW 610 and AFt‐GW 610
and B, GW 608‐Lys and AFt‐GW 608‐Lys. Data points are
mean ± standard deviation (SD), from three independent trials. For
sensitive carcinoma cell lines significant enhancement on uptake is
observed for Lys‐conjugated agent compared with insensitive MRC‐5
cells (P < 0.001; exemplified also in Figure S7)
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very low numbers of cells retained intracellular GW 610 or GW
608‐Lys following treatment with naked or AFt‐encapsulated agent
(eg, less than 8% MRC‐5 fibroblasts tested positive for intracellular
GW 610 or GW 608‐Lys). In contrast, a greater proportion of GW
610‐sensitive carcinoma cells carry sequestered GW 610 or GW
608‐Lys (Figure 3 and Supporting Information S3). The proportion of
GW 608‐Lys positive MCF‐7, TK10, IGROV‐1, and HCC2998 carci-
noma cells was greater following their exposure to AFt‐encapsulated
versus naked agent (correlating with greater potency of AFt‐GW
608‐Lys vs naked GW 608‐Lys; Figure 2). Of note also is the stark
increase in benzothiazole +ve cells (exemplified by MDA‐MB‐468)
between 3‐ and 9‐hour exposure, compared with a lower intracellular
accumulation of benzothiazoles encountered in, eg, TK10 cells; these
observations are consistent with the slower depletion of antitumour
benzothiazoes from nutrient medium of TK10 cells and slower induc-
tion of CYP 1A1 expression in these cells. Thus, multiple factors impact
the observed population of cells with detectable intracellular fluores-
cence including: (1) molecular polarity and diffusion across cell
membranes; (2) release rates of test agent from AFt cage; (3) the rate
of escape from endosomes; (4) cellular sequestration of benzothiazole,
dependent upon AhR signal transduction and CYP‐induction/expression and subsequent benzothiazole bioactivation; and (5) fluores-
cence changes following benzothiazole metabolism. Flow cytometry
provides a guide for understanding of the agent uptake in large cell
populations. However, to more comprehensively understand uptake,
release, and retention, further studies on individual cells would be
beneficial, adopting complementary techniques, such as labelling the
AFt cage and imaging both delivery vehicle and agent using time‐
dependent confocal microscopy.
An additional but distinct test was adopted to thoroughly explore
in vitro antitumour activity of AFt‐encapsulated GW 610 formula-
tions. In MCF‐7 clonogenic assays, AFt‐GW 610 (at GI50 value)
abolished colony formation. Nanomolar concentrations of GW 610
(450nM) and GW 608‐Lys (130nM) were able to significantly reduce
KM‐12 colony formation when encapsulated within AFt. Clonogenic
assays corroborated in vitro antitumour activity of AFt‐encapsulated
GW 610 and amino acid prodrugs. More specifically, they indicate that
these formulations possess cytotoxic properties and inhibit formation
of progeny colonies.3 | CONCLUSIONS
In conclusion, GW 610 has been successfully encapsulated within AFt
with more than 190 molecules per AFt cage, and the encapsulated
agent is more potent than naked GW 610 in 5/7 cell lines tested,
demonstrating up to 50‐fold enhanced activity against KM‐12 cells.
Conjugation to amino acids improved solubility and increased encap-
sulation efficiency of the agent. The most promising of these was
the GW 608‐Lys conjugate whose potency was significantly increased
following AFt‐encapsulation. The AFt cage enables sustained steady
release of the agent over 12 hour at physiological conditions (pH
and temperature). Cellular uptake of AFt‐encapsulated and naked
agents showed that AFt‐GW 608‐Lys is generally more readily and
rapidly sequestered by cells, correlating with more potent growth
inhibitory properties. We conclude that AFt‐GW 608‐Lys, which
combines potent and selective antitumour activity of parent GW
610 with biocompatibility of AFt delivery vehicle, presents a viable
putative anticancer therapy worthy of further preclinical development.4 | METHODS
All commercially available starting materials were used without further
purification. Nuclear magnetic resonance (NMR) spectra were recorded
on a Bruker AV (II) 500 at 500 MHz. High resolution mass spectra
(HRMS) were recorded on a Bruker microOTOFII with electrospray
ionization (ESI).4.1 | AFt encapsulation and drug release studies
AFt was prepared from horse spleen Ft (Sigma Aldrich) following a pro-
tocol developedWong et al30 (see Supporting Information S2).We have
shown in previous work encapsulating colloidal quantum dots in human
H‐ and horse spleen AFt, that the encapsulation methodology devel-
oped for one AFt type can be directly translated to the other AFt type.
6 of 7 BREEN ET AL.For encapsulation at 4°C, AFt (pH 7.4, 1.0 mL, 3.2 mg mL−1,
7.3 × 10−9 mol) was diluted ×2 in Hepes buffer (20mM, pH 7.4); test
agent (10mM in DMSO, 0.73 μL, 7.3 × 10−7 mol) was added 10 times
at 30‐minute intervals under stirring. The resulting solution was
dialyzed in tubing MWCO 12‐1400 against Hepes buffer (20mM,
pH 7.4, 1.5 L) for 16 hours to remove unencapsulated test agent,
centrifuged at 2.4 g for 5 minutes at 4°C to remove AFt precipitate,
and the supernatant was stored at 4°C.
The protein concentration of AFt was determined by Bradford
Assay. The test agent concentrations were determined by UV‐vis
absorbance on Varian Cary50 spectrometer. Encapsulation efficiency
(EE) and drug loading (DL) were calculated as amount of loaded drug
vs amount of total drug added and vs total amount of AFt/drug
composite, respectively.
Samples of AFt‐GW 610 and AFt‐GW 608‐Lys (2 mL) (0.2‐
0.4 mg mL−1 AFt concentration) were placed into dialysis bags
(MWCO 3.5 kDa) and immersed in 1.5 L of phosphate buffered saline
(PBS) at pH 6.5 and 7.4 (under N2 at 37°C). PBS was refreshed every
12 h. Aliquots (10 μL) from the dialysis bag were analysed by UV‐vis
absorbance.4.2 | In vitro cell culture studies
All cell lines were purchased from The American Type Culture Collec-
tion (ATCC) and cultured in RPMI 1640 medium supplemented with
10% foetal bovine serum (FBS) at 37°C in an atmosphere of 5%
CO2. Cells were passaged twice weekly to maintain continuous loga-
rithmic growth.
For MTT assays, cells were seeded at a density of 5 × 103 cells per
well into 96‐well plates and allowed 24 hours to adhere. Serial
dilutions were prepared in medium and added to cells (n = 4 per
concentration). Viable cells at the time of test agent addition
(T0) and following 72 hours of drug exposure were determined
by cell‐mediated 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium
bromide (MTT) reduction. MTT was added to each well (final con-
centration 400 μg mL−1) and incubated for 3 hours at 37°C. Well
supernatants were aspirated and formazan solubilized with 150 μL
DMSO. Absorbance was read at 550 nm using Perkin Elmer
Envision plate reader. The GI50 values were determined by
interpolation.
For cellular uptake studies, cells were seeded at a density of
2.5 × 105 cells per well into 12‐well plates and allowed 24 hours to
adhere. Cells were exposed to test agent (1 μM) for 3, 6 or 9 hours
before being washed, harvested and fixed in 3.7% formaldehyde.
Analyses were performed on a Beckman Coulter MoFlo Astrios EQ,
equipped with 355‐nm UV laser, 448/59 detection filter, and Summit
5.1 software. For colonogenic assays, 250 cells per well were seeded
into six‐well plates and allowed 24 hours to attach. Test compounds
were added at GI50 concentrations. After 24‐hour exposure, the
medium was aspirated and cells washed with PBS (2 × 1 mL) before
incubation in medium (2 mL) for 7 to 9 days. Experiments were termi-
nated when colonies more than or equal to 50 cells were observed in
control wells. Colonies were washed (PBS, 2 × 1 mL), fixed (methanol,
15 minutes), stained (0.5% methylene blue, 15 minutes), and counted.4.3 | Data analysis
All experiments were repeated at least three times and results are
reported as mean ± standard deviation (SD).
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